Climb Bio, Inc. - 8-K Filing
Climb Bio reports Phase 1 data for CLYM116 showing >90% APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CLYM
Read the full article at SEC EDGAR
Part of the story Climb Bio, Inc. - 8-K Filing (3 articles)